Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma

International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes

Journal of Clinical Oncology · 2008 · 2.1K citations

Medicine, Hematology, Pathology +14

Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma

Elise A. Olsen, Youn H. Kim, Timothy M. Kuzel et al. · Journal of Clinical Oncology · 2007 · 1K citations

Pharmacy, Oncology, Pharmacotherapy +16

Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

Bertrand Coiffier, Barbara Pro, H. Miles Prince et al. · Journal of Clinical Oncology · 2012 · 674 citations

Medicine, Pharmacology, Pharmacotherapy +13

Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

Owen A. O’Connor, Barbara Pro, Lauren Pinter‐Brown et al. · Journal of Clinical Oncology · 2011 · 643 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

A targeted mutational landscape of angioimmunoblastic T-cell lymphoma

Oreofe O. Odejide, Oliver Weigert, Andrew A. Lane et al. · Blood · 2013 · 429 citations · Full text

Medicine, Hematology, Oncology +11